GlobalData Plc

The viscosupplementation space in the Middle East and Africa, which includes the five major markets of Egypt, Israel, Saudi Arabia, South Africa, and the United Arab Emirates, is set to grow from $23.3 million in 2016 to around $37 million by 2023, representing a compound annual growth rate (CAGR) of 4.9%, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report states that key drivers of the market include the rising prevalence of osteoarthritis due to increasing aging and obese populations, the evolving multimodal treatment paradigm for osteoarthritis, and patients seeking to delay knee replacement surgery in an effort to maintain an active lifestyle.

Jennifer Ryan, Healthcare Analyst for GlobalData, explains: “Growth in the primary knee replacement market is likely to slow as patients increasingly seek conservative pain management options. Although these non-surgical treatments typically last only a few months, many patients willingly accept the durability tradeoff to avoid the cost and downtime associated with surgery.

“Worldwide, more than 90% of prescriptions written for viscosupplementation are for the management of knee osteoarthritis. With increasing investigation and evidence mounting in support of the efficacy of this treatment modality for osteoarthritis patients, its potential use in additional patient populations and for other pathologies affecting the synovial joints is being investigated. However, the current rate of technology diffusion of hyaluronic acids for hip and shoulder osteoarthritis is still low and is limited to the self-pay market.”

The viscosupplementation market is highly fragmented, with key players varying by region and country. In the Middle East and Africa, Sanofi, Ferring Pharmaceuticals, Anika Therapeutics, and Fidia Farmaceutici will dominate the field.

Unlike most orthopedic device markets, the viscosupplementation space is largely populated by pharmaceutical companies. Although many companies maintain a direct presence in the markets they sell to, some have co-ordinated marketing and distribution partnerships with major orthopedic players in an effort to leverage geographical experience and existing relationship with surgeons.

South Africa represented the largest portion of the market in 2016, holding almost 65% of the regional revenue, and is expected to maintain this dominance through the forecast period. GlobalData also expects South Africa to be the fastest-growing market to 2023, at a CAGR of 5.3%, while the slowest growth will be observed in the UAE at a CAGR of 3.2%.

– Information based on GlobalData’s report: MediPoint: Viscosupplementation – Middle East and Africa Analysis and Market Forecasts.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF